# Phase 3 recurrence trials recruiting: 43 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 43 trials in phase 3 for recurrence that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 recurrence trials: 43 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/recurrence

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 43
- Recruiting or not yet: 43
- Read on: November 19, 2026

## Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933432 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933432) |
| September 16, 2026 | NCT07822646 | A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer | Chinese PLA General Hospital | Phase 3 | Recruiting | Ovarian Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822646) |
| September 1, 2026 | NCT07797153 | JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 | Not yet recruiting | Recurrent or Metastatic Cervical Cancer | 368 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797153) |
| August 27, 2026 | NCT07790380 | FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell... | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Recruiting | Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With... | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790380) |
| August 25, 2026 | NCT07784101 | A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or... | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784101) |
| July 27, 2026 | NCT07728188 | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies... | AbbVie | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728188) |
| July 23, 2026 | NCT07723248 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With... | ORIC Pharmaceuticals | Phase 3 | Recruiting | Metastatic Castration Resistant Prostate Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723248) |
| June 3, 2026 | NCT07623798 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623798) |
| May 12, 2026 | NCT07579234 | A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety... | Shandong New Time Pharmaceutical Co., LTD | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 261 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07579234) |
| February 12, 2026 | NCT07406542 | A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Recurrent or Metastatic Breast Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406542) |
| January 15, 2026 | NCT07342478 | ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL | Newave Pharmaceutical Inc | Phase 3 | Recruiting | CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed, SLL (Small Lymphocytic Lymphoma), SLL... | 306 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07342478) |
| December 16, 2025 | NCT07286162 | Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer | University Health Network, Toronto | Phase 3 | Not yet recruiting | Ovarian Cancer (OvCa), Recurrent Ovarian Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286162) |
| October 27, 2025 | NCT07221253 | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | AstraZeneca | Phase 3 | Recruiting | Biliary Tract Cancer | 1,100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221253) |
| October 6, 2025 | NCT07208058 | A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory... | TJ Biopharma Co., Ltd. | Phase 3 | Recruiting | Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07208058) |
| September 29, 2025 | NCT07197580 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 | Recruiting | ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197580) |
| September 23, 2025 | NCT07189325 | A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting... | University Hospital, Montpellier | Phase 3 | Recruiting | Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189325) |
| September 10, 2025 | NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Genmab | Phase 3 | Recruiting | Endometrial Cancer, Recurrent or Progressive Endometrial Cancer | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166094) |
| August 22, 2025 | NCT07138209 | A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With... | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07138209) |
| August 22, 2025 | NCT07136987 | A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery | Open Source Pharma Foundation | Phase 3 | Not yet recruiting | Tuberculosis | 1,104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07136987) |
| August 5, 2025 | NCT07104032 | IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) | Ono Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Relapsed/Refractory Primary Central Nervous System Lymphoma | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104032) |
| July 14, 2025 | NCT07062965 | A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative... | Pfizer | Phase 3 | Recruiting | Breast Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07062965) |
| June 8, 2025 | NCT07011056 | A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 3 | Recruiting | Recurrent and Refractory Diffuse Large B-cell Lymphoma | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011056) |
| May 16, 2025 | NCT06976190 | A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic... | Lepu Biopharma Co., Ltd. | Phase 3 | Recruiting | Recurrent or Metastatic Nasopharyngeal Carcinoma | 446 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976190) |
| December 3, 2024 | NCT06713837 | IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 3 | Recruiting | Acute Myeloid Leukemia, Relapse/Recurrence | 339 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06713837) |
| September 26, 2024 | NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and... | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06615479) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| ORIC Pharmaceuticals | 1 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 1 |
| [Celgene](https://specstream.ai/data/clinical-trials/company/celgene) | 1 |
| University Health Network, Toronto | 1 |
| [Ono Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/ono-pharmaceutical-co-ltd) | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| University Hospital, Montpellier | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| [Chengdu Zenitar Biomedical Technology Co., Ltd](https://specstream.ai/data/clinical-trials/company/chengdu-zenitar-biomedical-technology-co-ltd) | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Open Source Pharma Foundation | 1 |
| Chinese Academy of Medical Sciences | 1 |
| [Shandong New Time Pharmaceutical Co., LTD](https://specstream.ai/data/clinical-trials/company/shandong-new-time-pharmaceutical-co-ltd) | 1 |
| Children's Hospital of Fudan University | 1 |
| [SecuraBio](https://specstream.ai/data/clinical-trials/company/securabio) | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| [Telix Pharmaceuticals (Innovations) Pty Limited](https://specstream.ai/data/clinical-trials/company/telix-pharmaceuticals-innovations-pty-limited) | 1 |
| Chinese PLA General Hospital | 1 |
| [TJ Biopharma Co., Ltd.](https://specstream.ai/data/clinical-trials/company/tj-biopharma-co-ltd) | 1 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |
| Sun Yat-sen University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 19 |
| France | 13 |
| United States | 11 |
| Italy | 10 |
| Spain | 10 |
| Australia | 9 |
| Canada | 9 |
| Germany | 9 |
| Belgium | 8 |
| Czechia | 8 |
| Poland | 8 |
| Japan | 7 |
| Brazil | 7 |
| United Kingdom | 7 |
| Israel | 6 |
| Taiwan | 6 |
| South Korea | 6 |
| Netherlands | 6 |
| Turkey (Türkiye) | 5 |
| Puerto Rico | 4 |
| Austria | 4 |
| Finland | 4 |
| Greece | 4 |
| Romania | 4 |
| Denmark | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [Landscaping companies in the United States](https://specstream.ai/data/businesses/landscaping-companies/united-states)
- [Furniture manufacturers in the United States](https://specstream.ai/data/businesses/furniture-manufacturers/united-states)
- [Damage restoration companies in the United States](https://specstream.ai/data/businesses/damage-restoration-companies/united-states)
- [Bathroom remodelers in the United States](https://specstream.ai/data/businesses/bathroom-remodelers/united-states)
- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
